Comparative evaluation of the results of treatment of prostate cancer non-steroidal antiandrogen mode and low-dose estrogen-therapy antiandrogenic
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Was performed a comparative evaluation of results of treatment with low-dose estrogen-antiandrogen therapy versus monotherapy with nonsteroidal antiandrogen for patient witth prostate cancer II-IV stages. The study group included 47 patients treated in the mode LDEAT (flutamide 250 mg 3 times/day in combination with sublingual chlortrianizen in subtherapeutic doses: 0.006 g, 2 times/day), in the control group was 88 patients treated with flutamide in the standard dose (250 mg 3 times / day). In the observation of the dynamics during treatment in both groups noted reduction in the intensity of complaints, increasing of urofloumetry parameters, reduction of prostate volume and PSA reduction without significant differences between groups of these indicators. Indicators of general and cancer-specific survival between the two groups also were not statistically different (p>0,05). The combined use of flutamide in LDEAT mode allows to achieve a significant therapeutic effect in a short time with less severe side effects and improve survival rates and quality of life.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Ferlay J., Autier P., Boniol M. Estimates of the cancer incidence and mortality in Europe in 2010 // Ann. Oncol. – 2011. – 18. – 581–92.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 (2): 71–96. http://www.ncbi.nlm.nih.aov/pubmed/18287387
Parkin DM, Bray Fl, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37 (Suppl8): S4-66. http://www.ncbi.nlm.nih.gOv/pubmed/11602373
Бюлетень Національного канцерреєстру No 16 – «Рак в Україні, 2013–2014»
Возианов А.Ф. Эндокринная терапия рака предстательной железы / А.Ф. Возианов, А.Г. Резников, И.А. Клименко. – К.: Наук. думка, 1999. – 175 с.
Имянитов Е.Н. Эпидемиология и биология рака простаты / Е.Н. Имянитов // Практическая онкология. – Том 9, No 2. – 2008. – С. 57–64.
Iversen P. и др. Сравнительный анализ результатов монотерапии бикалютамидом и кастрации у больных неместатическим местно-распространенном РПЖ при сроке наблюдения 6,3 года // Онкоурология. – 2006. – Спецвып. 2. – С. 4–10.
Moul JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 2009 Aug;115(15):3376–8. http://www.ncbi.nlm.nih.gov/pubmed/19484788 (no abstract).
Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009 Jun;55 (6):1269–77.
Григоренко В.М. Експериментальне обґрунтування та клінічні ефекти монотерапії і комбінованого застосування хлортріанізену та флутаміду у стандартних та редукованих дозах при лікуванні РПЗ / В.М. Григоренко, Л.В. Чайковська, Л.І. Полякова, О.В. Сачинська // Здоровье мужчины. – 2010. – No 1 (32). – С. 163–169.
